VJHemOnc is committed to improving our service to you

COMy 2019 | Updates on German clinical trials in multiple myeloma

VJHemOnc is committed to improving our service to you

Marc Raab

Marc Raab, MD, PhD, of University Hospital Heidelberg, Heidelberg, Germany, gives an overview of recently concluded and ongoing German clinical trials looking at multiple myeloma (MM) treatment. For example, Prof. Raab discusses the results from the GMMG-MM5 trial (EudraCT no. 2010-019173-16), which compares a fixed two-year period of lenalidomide maintenance with stopping maintenance after complete remission. Prof. Raab also explains how two ongoing trials are likely to present interesting results on the role of monoclonal antibodies in first-line setting. This interview took place at the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter